Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OTC Switch Interest Cooled By Study Costs To Update Safety Data

Executive Summary

Firms often are hesitant to prepare Rx-to-OTC switch applications because safety and efficacy data for their products are over a decade old, notes health care consultant Laura Mahecha.


Related Content

FDA's OTC Naloxone Study Is A Starting Point For Other Switches, Not A Roadmap
Petition Seeks OTC PPI Warning On Cancer Risk From Persistent Heartburn
Pharma Firm ISO OTC Switch Partner; NDA Experience, Resources Needed
Differin Gel Enters Changed Marketplace Since Last OTC Acne Drug Approval
Merck Silence On OTC Singulair Speaks Volumes On Switch Outlook
Light Still On For Switches After Pfizer Pulls Plug On OTC Lipitor
Room For Innovative Switches Could Lurk In Existing FDA Framework
Naloxone Talk Sheds Light On Switch Research Future


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts